Pharmacological Treatments and Natural Biocompounds in Weight Management
暂无分享,去创建一个
Geir Bjørklund | Yu O Semenova | Amin Gasmi | A. Menzel | P. Mujawdiya | S. Piscopo | M. Shanaida | V. Shanaida | V. Voloshyn | P. K. Mujawdiya | Volodymyr Shanaida | Amine Nehaoua | O. Voloshyn
[1] M. Peana,et al. The Role of Astaxanthin as a Nutraceutical in Health and Age-Related Conditions , 2022, Molecules.
[2] Monica Butnariu,et al. Natural Compounds and Products from an Anti-Aging Perspective , 2022, Molecules.
[3] L. Oyama,et al. Ginkgo biloba Extract Stimulates Adipogenesis in 3T3-L1 Preadipocytes , 2022, Pharmaceuticals.
[4] Jingxin Zhang,et al. Multidisciplinary Progress in Obesity Research , 2022, Genes.
[5] M. Peana,et al. Polyphenols in Metabolic Diseases , 2022, Molecules.
[6] Xi-Ding Yang,et al. Potential lipolytic regulators derived from natural products as effective approaches to treat obesity , 2022, Frontiers in Endocrinology.
[7] Sohita Dhillon. Phentermine/Topiramate: Pediatric First Approval , 2022, Pediatric Drugs.
[8] Meihong Xu,et al. Adipose Tissue Aging and Metabolic Disorder, and the Impact of Nutritional Interventions , 2022, Nutrients.
[9] Jailane de Souza Aquino,et al. Effects of the Treatment with Flavonoids on Metabolic Syndrome Components in Humans: A Systematic Review Focusing on Mechanisms of Action , 2022, International journal of molecular sciences.
[10] S. Bielinski,et al. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study , 2022, BMC Medicine.
[11] M. Konwar,et al. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis , 2022, International journal of clinical practice.
[12] Jun Yu Li,et al. Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities , 2022, Pharmaceutics.
[13] W. Shi,et al. Hypothesis: Amelioration of obesity‐induced cognitive dysfunction via a lorcaserin–betahistine combination treatment , 2022, Pharmacology research & perspectives.
[14] D. Goulis,et al. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease , 2022, Current Obesity Reports.
[15] E. Helal,et al. Effects of the Antiobesity Drugs Aplex and Venera on Certain Biochemical and Physiological Indices in Obese Adult Male Albino Rats , 2022, Advances in pharmacological and pharmaceutical sciences.
[16] W. Chung,et al. Effects of electroacupuncture for obesity , 2022, Medicine.
[17] Jiankang Cao,et al. Anti-diabetic and anti-obesity: Efficacy evaluation and exploitation of polyphenols in fruits and vegetables. , 2022, Food research international.
[18] R. Matos,et al. Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats. , 2022, The Journal of endocrinology.
[19] Md. Rezaul Islam,et al. The Multifunctional Role of Herbal Products in the Management of Diabetes and Obesity: A Comprehensive Review , 2022, Molecules.
[20] M. Farré,et al. Abuse Potential of Cathinones in Humans: A Systematic Review , 2022, Journal of clinical medicine.
[21] A. Nicolucci,et al. The adolescent with obesity: what perspectives for treatment? , 2022, Italian Journal of Pediatrics.
[22] M. Lam,et al. Dosing Therapeutic Radiopharmaceuticals in Obese Patients , 2022, International journal of molecular sciences.
[23] D. Pellegrino,et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery , 2021, Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.
[24] G. Guyatt,et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials , 2021, The Lancet.
[25] M. Horowitz,et al. Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop , 2021, Drug and Therapeutics Bulletin.
[26] Lu Zhang,et al. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients , 2021, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[27] Beverly G. Tchang,et al. Obesity and Diabetes. , 2021, The Nursing clinics of North America.
[28] O. Meijer,et al. Variation in glucocorticoid sensitivity and the relation with obesity , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[29] M. Tschöp,et al. Anti-obesity drug discovery: advances and challenges , 2021, Nature reviews. Drug discovery.
[30] C. Matthys,et al. Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved , 2021, Obesity Facts.
[31] D. Ryan. Drugs for Treating Obesity. , 2021, Handbook of experimental pharmacology.
[32] Ding Li,et al. Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets , 2021, Frontiers in Pharmacology.
[33] A. D’Anneo,et al. The Beneficial Effects of Essential Oils in Anti-Obesity Treatment , 2021, International journal of molecular sciences.
[34] C. Mantzoros,et al. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. , 2021, Endocrine reviews.
[35] N. Salari,et al. The best drug supplement for obesity treatment: a systematic review and network meta-analysis , 2021, Diabetology & Metabolic Syndrome.
[36] Y. Jee,et al. Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice. , 2021, The Journal of nutritional biochemistry.
[37] H. Hauner. [Obesity treatment-legal and illegal drugs and the future]. , 2021, Der Internist.
[38] H. Hauner. Adipositastherapie – legale und illegale Arzneimittel und die Zukunft , 2021, Der Internist.
[39] R. Bove,et al. Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist , 2021, Journal of the Neurological Sciences.
[40] M. Kumar,et al. Nano-Derived Therapeutic Formulations with Curcumin in Inflammation-Related Diseases , 2021, Oxidative medicine and cellular longevity.
[41] Hyo-Jin An,et al. Papain Ameliorates Lipid Accumulation and Inflammation in High-Fat Diet-Induced Obesity Mice and 3T3-L1 Adipocytes via AMPK Activation , 2021, International journal of molecular sciences.
[42] J. Roncalli,et al. Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice , 2021, International journal of molecular sciences.
[43] S. Robinson,et al. Clinical outcomes associated with anti‐obesity medications in real‐world practice: A systematic literature review , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[44] R. Molinari,et al. Polyphenols as modulators of pre‐established gut microbiota dysbiosis: State‐of‐the‐art , 2021, BioFactors.
[45] I. C. Tudor,et al. Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects , 2021, Journal of clinical psychopharmacology.
[46] S. Granica,et al. Highbush Blueberry (Vaccinium corymbosum L.) Leaves Extract and Its Modified Arginine Preparation for the Management of Metabolic Syndrome—Chemical Analysis and Bioactivity in Rat Model , 2021, Nutrients.
[47] A. Mirzababaei,et al. Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials , 2021, International journal of clinical practice.
[48] V. Petrikaitė,et al. Bio-guided bioactive profiling and HPLC-DAD fingerprinting of Ukrainian saffron (Crocus sativus stigmas): moving from correlation toward causation , 2021, BMC Complementary Medicine and Therapies.
[49] Dhiren Patel,et al. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity , 2021, Expert review of clinical pharmacology.
[50] M. Banach,et al. Quercetin and metabolic syndrome: A review , 2021, Phytotherapy research : PTR.
[51] K. Sharma,et al. A Review on Obesity Management through Natural Compounds and a Green Nanomedicine-Based Approach , 2021, Molecules.
[52] T. Gojobori,et al. Leptin and Obesity: Role and Clinical Implication , 2021, Frontiers in Endocrinology.
[53] R. Radice,et al. Effects of astaxanthin in animal models of obesity-associated diseases: a systematic review and meta-analysis. , 2021, Free radical biology & medicine.
[54] Jia Li,et al. Mechanism of Action of Acupuncture in Obesity: A Perspective From the Hypothalamus , 2021, Frontiers in Endocrinology.
[55] Hongjun Yang,et al. Celastrol in Metabolic Diseases: Progress and Application Prospects. , 2021, Pharmacological research.
[56] T. Lyons,et al. Dietary Blueberry and Soluble Fiber Supplementation Reduces Risk of Gestational Diabetes in Women with Obesity in a Randomized Controlled Trial. , 2021, The Journal of nutrition.
[57] P. Hellström,et al. Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose , 2021, Clinical pharmacology in drug development.
[58] A. Hichami,et al. Antioxidant and Anti-Inflammatory Potential of Polyphenols Contained in Mediterranean Diet in Obesity: Molecular Mechanisms , 2021, Molecules.
[59] M. Soto,et al. Oxidative Stress, Plant Natural Antioxidants, and Obesity , 2021, International journal of molecular sciences.
[60] M. Moorthy,et al. Polyphenols as Prebiotics in the Management of High-Fat Diet-Induced Obesity: A Systematic Review of Animal Studies , 2021, Foods.
[61] P. Taub,et al. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives , 2021, Nutrients.
[62] P. Hale,et al. A randomized, controlled trial of liraglutide for adolescents with obesity , 2020 .
[63] Ming Lyu,et al. The potential of artemisinins as anti-obesity agents via modulating the immune system. , 2020, Pharmacology & therapeutics.
[64] J. Pérez-Correa,et al. Phlorotannins: From isolation and structural characterization, to the evaluation of their antidiabetic and anticancer potential. , 2020, Food research international.
[65] M. Arshad,et al. Health benefits of xylitol , 2020, Applied Microbiology and Biotechnology.
[66] Xiang‐Dong Wang,et al. Lycopene in protection against obesity and diabetes: A mechanistic review. , 2020, Pharmacological research.
[67] K. Gadde,et al. The limits and challenges of antiobesity pharmacotherapy. , 2020, Expert opinion on pharmacotherapy.
[68] P. Hale,et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. , 2020, The New England journal of medicine.
[69] E. Harasim-Symbor,et al. Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol , 2020, Frontiers in Endocrinology.
[70] W. Garvey,et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial , 2020, Diabetes Care.
[71] M. T. Islam,et al. Anti‐obesity effect of plant diterpenes and their derivatives: A review , 2020, Phytotherapy research : PTR.
[72] S. Engeli,et al. Modern pharmacological treatment of obese patients , 2020, Therapeutic advances in endocrinology and metabolism.
[73] T. Meng,et al. The effect of beinaglutide on visceral fat and bodyweight in obese type 2 diabetic patients , 2020 .
[74] S. Chirumbolo,et al. Calanus oil in the treatment of obesity-related low-grade inflammation, insulin resistance, and atherosclerosis , 2019, Applied Microbiology and Biotechnology.
[75] B. Tomlinson,et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity , 2019, Expert opinion on pharmacotherapy.
[76] Naglaa F. Khedr,et al. New insights into weight management by orlistat in comparison with cinnamon as a natural lipase inhibitor , 2019, Endocrine.
[77] J. Marier,et al. A randomized, double‐blind, placebo‐controlled, pharmacokinetic and pharmacodynamic study of a fixed‐dose combination of phentermine/topiramate in adolescents with obesity , 2019, Diabetes, obesity & metabolism.
[78] K. Saunders,et al. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity , 2019, Expert opinion on pharmacotherapy.
[79] J. J. Gorgojo-Martínez,et al. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study , 2019, International journal of clinical practice.
[80] M. Todtenkopf,et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates , 2019, Journal of psychopharmacology.
[81] L. Mounien,et al. Anti-Obesity Effect of Carotenoids: Direct Impact on Adipose Tissue and Adipose Tissue-Driven Indirect Effects , 2019, Nutrients.
[82] Y. Jia,et al. Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study , 2019, Obesity science & practice.
[83] D. Fuchs,et al. Weight Gain During Treatment of Bipolar Disorder (BD)—Facts and Therapeutic Options , 2019, Front. Nutr..
[84] A. Soukas,et al. Metformin: Mechanisms in Human Obesity and Weight Loss , 2019, Current Obesity Reports.
[85] A. Bueno,et al. Potential Anti-obesogenic Effects of Ginkgo biloba Observed in Epididymal White Adipose Tissue of Obese Rats , 2019, Front. Endocrinol..
[86] H. Ashrafian,et al. Current treatments for obesity. , 2019, Clinical medicine.
[87] D. Majerowicz,et al. Pharmacotherapy of Obesity: Limits and Perspectives , 2019, American Journal of Cardiovascular Drugs.
[88] F. Greenway,et al. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis , 2019, International Journal of Obesity.
[89] Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers , 2018, Clinical Diabetes.
[90] O. Ruban,et al. Evaluation of anti-obesity and lipid-lowering properties of Vaccinium myrtillus leaves powder extract in a hamster model , 2018, Journal of basic and clinical physiology and pharmacology.
[91] R. Delorme,et al. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis , 2018, CNS Drugs.
[92] F. Punzo,et al. Role of Cannabinoids in Obesity , 2018, International journal of molecular sciences.
[93] Marc P. Bonaca,et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients , 2018, The New England journal of medicine.
[94] E. Lara-Padilla,et al. Anorectic efficacy and safety of the diethylpropion‐topiramate combination in rats , 2018, Drug development research.
[95] F. Greenway,et al. Centrally Acting Agents for Obesity: Past, Present, and Future , 2018, Drugs.
[96] R. Kushner. Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. , 2018, Progress in cardiovascular diseases.
[97] M. Gulliford,et al. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study , 2018, British Medical Journal.
[98] M. Alkafafy,et al. Physiological and molecular study on the anti-obesity effects of pineapple (Ananas comosus) juice in male Wistar rat , 2018, Food Science and Biotechnology.
[99] S. Cabaro,et al. Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths , 2018, Clinical Drug Investigation.
[100] Xiguang Qi. Review of the Clinical Effect of Orlistat , 2018 .
[101] Michelle Pearlman,et al. The Association Between Artificial Sweeteners and Obesity , 2017, Current Gastroenterology Reports.
[102] L. Gaal,et al. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options , 2017, Journal of Endocrinological Investigation.
[103] K. Kim,et al. Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? , 2017, Journal of obesity & metabolic syndrome.
[104] S. Thomas-Valdés,et al. Association between vitamin deficiency and metabolic disorders related to obesity , 2017, Critical reviews in food science and nutrition.
[105] E. Al-Dujaili,et al. Polyphenols and Their Role in Obesity Management: A Systematic Review of Randomized Clinical Trials , 2017, Phytotherapy research : PTR.
[106] Xinhua Xiao,et al. Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications , 2017, Bioscience reports.
[107] A. Mehta,et al. Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.
[108] Phang Siew-Moi,et al. Marine Algae as a Potential Source for Anti-Obesity Agents , 2016, Marine drugs.
[109] Jeffrey K. Aronson,et al. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review , 2016, BMC Medicine.
[110] F. Araniti,et al. Effects of Saponins on Lipid Metabolism: A Review of Potential Health Benefits in the Treatment of Obesity , 2016, Molecules.
[111] M. Pervin,et al. Beneficial Effects of Tea and the Green Tea Catechin Epigallocatechin-3-gallate on Obesity , 2016, Molecules.
[112] R. Fain,et al. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. , 2016, Clinical therapeutics.
[113] C. Tek. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives , 2016, Patient preference and adherence.
[114] S. Simon,et al. The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction , 2016, Appetite.
[115] J. Rey,et al. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. , 2016, P & T : a peer-reviewed journal for formulary management.
[116] Ralph Mazitschek,et al. Treatment of Obesity with Celastrol , 2015, Cell.
[117] N. D’Orazio,et al. Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin , 2015, Marine drugs.
[118] Martínez Díaz,et al. Cost-Effectiveness Analysis of Amfepramone (Diethylpropion) for the Obesity Treatment In Mexico. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[119] M. Cowley,et al. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. , 2014, Pharmacological research.
[120] D. Segula. Complications of obesity in adults: a short review of the literature. , 2014, Malawi medical journal : the journal of Medical Association of Malawi.
[121] S. Waldman,et al. Antiobesity Pharmacotherapy: New Drugs and Emerging Targets , 2013, Clinical pharmacology and therapeutics.
[122] S. Yanovski,et al. Long-term drug treatment for obesity: a systematic and clinical review. , 2014, JAMA.
[123] K. Gadde,et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults , 2013, Obesity.
[124] Barakatun Nisak Mohd Yusof,et al. Saffron: A Natural Potent Antioxidant as a Promising Anti-Obesity Drug , 2013, Antioxidants.
[125] Ariane O Conrad,et al. Phentermine and topiramate for the management of obesity: a review , 2011, Drug design, development and therapy.
[126] B. Schehler,et al. Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity , 2012, Experimental and Clinical Endocrinology & Diabetes (Barth).
[127] M. Tschöp,et al. Anti-obesity drugs: past, present and future , 2012, Disease Models & Mechanisms.
[128] M. Dietrich,et al. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons , 2012, Nature Reviews Drug Discovery.
[129] A. Ismail,et al. Plants' Metabolites as Potential Antiobesity Agents , 2012, TheScientificWorldJournal.
[130] J. Kang,et al. Anti-Obesity Drugs: A Review about Their Effects and Safety , 2012, Diabetes & metabolism journal.
[131] K. Gadde,et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.
[132] J. Ogden,et al. Taking Orlistat: Predicting Weight Loss over 6 Months , 2010, Journal of obesity.
[133] J. Crippa,et al. The psychiatric side-effects of rimonabant. , 2009, Revista brasileira de psiquiatria.
[134] A. Halpern,et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects , 2004, International Journal of Obesity.
[135] Maurizio Fava,et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. , 2005, Primary care companion to the Journal of clinical psychiatry.
[136] M. Stock,et al. Pharmacological characterisation of the thermogenic effect of bupropion. , 2004, European journal of pharmacology.
[137] S. O’Meara,et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[138] K. Gadde,et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. , 2001, Obesity research.
[139] R B Haynes,et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. , 2000, Archives of internal medicine.
[140] M. Korda,et al. [Status of the free radical oxidation and antioxidant system in rats with toxic liver damage; effect of tocopherol and dimethylsulfoxide]. , 1991, Ukrainskii biokhimicheskii zhurnal.
[141] J. Vallé-Jones,et al. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. , 1983, Pharmatherapeutica.